`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`In re Entresto (sacubitril/valsartan) Patent
`Litigation
`
`C.A. No. 20-md-2930-RGA
`
`C.A. No. 23-401-RGA
`
`NOVARTIS PHARMACEUTICALS
`CORPORATION,
`
`Plaintiff,
`
`v.
`
`NANJING NORATECH
`PHARMACEUTICAL CO., LIMITED,
`
`Defendant.
`
`FINAL JUDGMENT REGARDING U.S. PATENT NO. 8,101,659
`PURSUANT TO FEDERAL RULE OF CIVIL PROCEDURE 54(b)
`
`WHEREAS Plaintiff NOVARTIS PHARMACEUTICALS CORPORATION
`
`(“Novartis”) filed suit on April 10, 2023, alleging that Defendant NANJING NORATECH
`
`PHARMACEUTICAL CO., LIMITED (“Noratech”) infringed U.S. Patent No. 8,101,659 (“the
`
`’659 patent”) and U.S. Patent No. 11,058,667 (“the ’667 Patent”) by virtue of filing ANDA No.
`
`213671 for sacubitril/valsartan tablets, 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg (“the
`
`Noratech ANDA Products”);
`
`WHEREAS, on July 21, 2023, the Court entered a final judgment in MDL No. 20-2930
`
`and certain related cases (MDL No. 20-2930-RGA, D.I. 1120; C.A. No. 19-1979-RGA, D.I. 649;
`
`C.A. No. 19-2021-RGA, D.I. 245; C.A. No. 19-2053-RGA, D.I. 406) (“Delaware Final
`
`Judgment”), finding claims 1-4 of the ’659 patent invalid under 35 U.S.C. § 112 for lack of
`
`1
`
`
`
`
`
`Case 1:23-cv-00401-RGA Document 29 Filed 08/16/23 Page 2 of 4 PageID #: 205
`
`written description for the reasons set forth in the Court’s Trial Opinion dated July 7, 2023
`
`(MDL No. 20-2930-RGA, D.I. 1099);
`
`WHEREAS, on July 24, 2023, Novartis filed notices of appeal to the Federal Circuit
`
`from the Delaware Final Judgment, and its appeals are now pending in the Federal Circuit (MDL
`
`No. 20-2930-RGA, D.I. 1121, 1133; C.A. No. 19-1979-RGA, D.I. 650, 651; C.A. No. 19-2021-
`
`RGA, D.I. 246, 247; C.A. No. 19-2053-RGA, D.I. 407, 408);
`
`WHEREAS Novartis and Noratech agree that the Court’s final judgment in MDL No. 20-
`
`2930 (MDL No. 20-2930-RGA, D.I. 1120) that claims 1-4 of the ’659 patent are invalid for lack
`
`of written description applies in this action under the principles of collateral estoppel, and subject
`
`to the outcome of Novartis’s appeals;
`
`WHEREAS Novartis and Noratech agree that under Fed. R. Civ. P. 54(b) that the Court
`
`may, subject to appeal, direct entry of a final judgment against Novartis relating to the ’659
`
`patent on collateral estoppel grounds because there is no just reason for delay;
`
`WHEREAS Novartis and Noratech agree that, after Novartis files its appeal from entry of
`
`final judgment in this action, they will submit a joint motion in the Federal Circuit for a stay of
`
`the appeal from this action pending the outcome of Novartis’s appeals from the Delaware Final
`
`Judgment because if the Delaware Final Judgment is reversed or vacated, Novartis would be
`
`entitled to an order from the Federal Circuit vacating the judgment in this action and remanding
`
`this action to this Court for further proceedings or an order from this Court vacating the final
`
`judgment under Fed. R. Civ. P. 60(b)(5);
`
`IT IS ORDERED that pursuant to Fed. R. Civ. P. 54(b), there is no just reason to delay
`
`entry of a final judgment on collateral estoppel grounds with regard to the ’659 patent; and it is
`
`further
`
`
`
`2
`
`
`
`
`
`Case 1:23-cv-00401-RGA Document 29 Filed 08/16/23 Page 3 of 4 PageID #: 206
`
`ORDERED AND ADJUDGED, that under the principles of collateral estoppel, Final
`
`Judgment is hereby entered pursuant to Fed. R. Civ. P. 54(b) in favor of Noratech and against
`
`Novartis that claims 1-4 of the ’659 patent are invalid for lack of written description under 35
`
`U.S.C. § 112; and it is further
`
`ORDERED that all other pending claims and defenses relating to the ’659 patent are
`
`dismissed as moot, but with the Parties’ express acknowledgement that these other claims and
`
`defenses would revive if this Final Judgment is reversed or vacated; and it is further
`
`ORDERED that each party shall bear its own costs and fees.
`
`
`
`
`
`
`
`3
`
`
`
`Case 1:23-cv-00401-RGA Document 29 Filed 08/16/23 Page 4 of 4 PageID #: 207
`
`Dated: August 16, 2023
`
`McCARTER & ENGLISH, LLP
`
`/s/ Daniel M. Silver
`Daniel M. Silver (#4758)
`Alexandra M. Joyce (#6423)
`Renaissance Centre
`405 N. King Street, 8th Floor
`Wilmington, Delaware 19801
`(302) 984-6300
`dsilver@mccarter.com
`ajoyce@mccarter.com
`
`HEYMAN ENERIO GATTUSO &
`HIRZEL LLP
`
`/s/ Dominick T. Gattuso
`Dominick T. Gattuso
`300 Delaware Avenue, Suite 200
`Wilmington, DE 19801
`(302) 472-7311
`dgattuso@hegh.law
`
`Attorney for Defendant Nanjing Noratech
`Pharmaceutical Co., Limited
`
`Attorneys for Plaintiff Novartis
`Pharmaceuticals Corporation
`
`OF COUNSEL:
`
`HUSCH BLACKWELL LLP
`Don J. Mizerk (pro hac vice)
`120 South Riverside Plaza, Suite 2200
`Chicago, IL 60606
`(312) 655-1500
`don.mizerk@huschblackwell.com
`
`OF COUNSEL:
`
`Nicholas N. Kallas
`Christina Schwarz
`Christopher E. Loh
`Jared L. Stringham
`VENABLE LLP
`151 West 42nd Street
`New York, New York 10036
`(212) 307-5500
`nkallas@venable.com
`cschwarz@venable.com
`cloh@venable.com
`jlstringham@venable.com
`
`16
`August
`/s/Richard G. Andrews
`Dated this ___ day of ______________, 2023. __________________________________
`United States District Court Judge
`
`4
`
`